Abdulazeez lhussein Alhussein - Department of Chemical and Process Engineering, Faculty of Engineering and Built Environment, University Kebangsaan Malaysia (UKM), Bangi P.O. Box ۴۳۰۰۰, Selangor, Malaysia
Tayser Gaaz - Department of Chemical and Process Engineering, Faculty of Engineering and Built Environment, University Kebangsaan Malaysia (UKM), Bangi P.O. Box ۴۳۰۰۰, Selangor, Malaysia
Ahed Jaaz - Medical Physics Department, College of Science, Al-Mustaqbal University, Babylon, Iraq
Forat Alsultany - Medical Physics Department, College of Science, Al-Mustaqbal University, Babylon, Iraq
Abdul Amir H. Kadhum - College of Medicine, University of Al-Ameed, Karbala, Iraq
Ahmed Al-Amiery - Department of Chemical and Process Engineering, Faculty of Engineering and Built Environment, University Kebangsaan Malaysia (UKM), Bangi P.O. Box ۴۳۰۰۰, Selangor, Malaysia
Hussein Al-Bahrani - Department of Chemistry, College of Education for Pure Science, University of Kerbala, Karbala, Iraq

When nanotechnology is used in medicine, it makes it easier to find and treat a wide range of diseases. The potentially fatal disease multiple sclerosis (MS) has a disproportionately large impact on young people. One of the oral options for treating this condition is dimethyl fumarate (DMF). This study aimed to use platelet membranes and polymeric nanoparticles (PNs) to develop a drug delivery system that mimics biological cells to treat MS. Here, we produced and characterized solid lipid nanoparticles (SLNs) containing dimethyl fumarate (DMF). To make SLNs, DMF is combined with biocompatible lipids using hot emulsion and ultrasonication techniques. These DMF-SLNs were characterized using transmission electron microscopy (TEM), scanning electron microscopy (SEM), FTIR spectroscopy, and a zeta meter instrument. Characterization revealed that the optimal SLNs had a polydispersity index of (۰.۲۸, ۰.۹۶, ۰.۷۷), a zeta potential of (-۲۲.۷۳ mV, -۲۸.۷ mV, and -۳۰.۱۳ mV), and a mean particle size of (۵۶۲ nm, ۱۹۹۷ nm, and ۸۴۹ nm). The results of this study suggest that the present formulation may be a potential longer-acting formulation for the improved management of MS. SLNs could significantly change the treatment of many illnesses by providing effective drug delivery.

Multiple Sclerosis, Dimethyl fumarate, Immunomodulatory fumaric acid